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In contrast to the idea that hippocampal and amygdala volume loss occur in
late phases of neurodegeneration, recent contributions point to the relevance of
preexisting structural deficits that are associated with aging and are independent
of amyloid deposition in preclinical Alzheimer disease cases. The present work
explores GM hippocampal and amygdala volumes in elderly controls displaying the
first signs of cognitive decline. 455 subjects (263 females), including 374 controls
(228 females) and 81 middle cognitive impairment subjects (35 females), underwent
two neuropsychological evaluations (baseline and 18 months follow-up) and a MRI-T1
examination (only baseline). Clinical assessment included Mini-Mental State Examination
(MMSE), Clinical Dementia Rating scale, Hospitalized Anxiety and Depression scale, the
Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological battery
and RI-48 Cued Recall Test (RI-48) for episodic memory. Based on their cognitive
performance, we defined the controls as stable controls (sCON) and deteriorating
controls (dCONs). Analyses included volumetric assessment, shape analyses and
linear regressions between GM volume loss and differences in clinical scores between
baseline and follow-up. Significant GM volume decrease in hippocampus bilaterally
and right amygdala was found in dCON compared to sCON (p < 0.05). Lower right
amygdala volumes were measured in mild cognitive impairment (MCI) compared to
sCON (p < 0.05). Shape analyses revealed that atrophy was more pronounced at
the superior- posterior lateral side of the hippocampus and amygdala. Significant
correlations were found between GM volume of left hippocampus and the delta of
MMSE and RI-48 scores in dCON and MCI groups separately. Decreased hippocampal
and right amygdala volumes precede the first signs of cognitive decline in healthy elderly
controls at the pre-MCI state. Left hippocampus volume may also predict short-term
changes of overall cognition in these vulnerable cases.
Keywords: hippocampus, amygdala, Alzheimer, FSL FIRST, MCI, cognitive impairment, deteriorating controls
Frontiers in Aging Neuroscience | www.frontiersin.org 1 March 2017 | Volume 9 | Article 50
fnagi-09-00050 March 7, 2017 Time: 17:18 # 2
Zanchi et al. Limbic System Atrophy and Cognitive Decline
INTRODUCTION
The first neuropathological hallmarks described by Alois
Alzheimer more than a century ago, amyloid deposits and
neurofibrillary tangles (NFTs), are present in hippocampal
subdivisions and restricted neocortical areas of cognitively
normal people and their densities increase with age
(Giannakopoulos et al., 2007). Progressively, AD pathogenesis
has been perceived as a long lasting morbid process, with an
extensive prodromal phase. Subsequent advent of modern
non-invasive diagnostic techniques enabled early detection of
diverse AD-related pathological events in vivo, and prepared
the ground for the notion of preclinical AD (Lazarczyk et al.,
2012). This concept refers to asymptomatic stages of AD that are
characterized by the progressive development of functional and
subsequently structural changes in cortical areas in the absence of
clinically overt signs of the disease. Early appearance of various
biological changes suggestive of AD pathology in controls has
been extensively documented. They may precede clinically
overt dementia by many years, or even decades (Reiman et al.,
2004; Shaw et al., 2007; Lazarczyk et al., 2012), thus defining a
temporally wide preclinical phase of the disease (Lazarczyk et al.,
2012).
The appearance of these preclinical markers has been
described as a highly ordered process summarized by Jack
et al. (2010) in their sequential model of the evolution of AD.
According to this model, the earliest AD markers are those related
to amyloid deposits in Positron emission tomography (PET)
with Pittsburg compound B (Fagan et al., 2006; Forsberg et al.,
2010), followed by increased cerebrospinal fluid (CSF) tau and
phospho-tau levels (Fagan et al., 2009), brain hypometabolism
in FDG- PET (18-Fluorodeoxy-glucose PET), and abnormal
activation pattern in functional magnetic resonance imaging
(fMRI) upon cognitive task solving (Liang et al., 2011; Miao et al.,
2011). Initially, very subtle morphological brain alterations were
thought to become detectable in structural magnetic resonance
imaging (MRI) only in later phases of neurodegeneration
in preclinical AD, notably, a decrease in entorhinal cortex,
hippocampal and amygdala volume (Miller et al., 2013; Younes
et al., 2014).
A recently published work on 1209 cognitively intact
individuals (Jack et al., 2015) showed that hippocampal volume
loss may occur before abnormal amyloid PET occurrence
pointing to the relevance of preexisting structural deficits that
are associated with aging and are independent on the current
amyloid pathology-determined definition of preclinical AD.
Similar observations were reported by Edmonds indicating that
neurodegeneration alone was 2.5 times more common than
amyloidosis alone among healthy individuals who subsequently
progress to mild cognitive impairment (MCI) (Edmonds et al.,
2015).
The current investigation aims to extend the established
findings of GM loss in the earliest stage of cognitive decline
before MCI or even AD. We assessed of 455 elderly individuals
(mean age, 73.5 ± 4.2 years, 263 females) including notably
374 healthy controls with intact cognitive status at inclusion.
Based on neurocognitive follow-up at 18 months about half of
controls remained cognitively stable (sCON), while the other
half had subtle cognitive deteriorating control (dCON). It is
important to emphasize, that even the dCON participants at
follow-up were still in the range of normal cognitive performance,
yet with respect to the baseline assessment, these participants
expressed first subtle cognitive deficits, clearly less pronounced to
qualify for an MCI state. We explored the patterns of GM loss in
hippocampus and amygdala in these elderly controls displaying
the first signs of cognitive decline as compared to stable controls
as well as MCI cases as a second group of comparison.
MATERIALS AND METHODS
Participants
The protocol was approved by the ethics committee of the
University Hospitals of Geneva. All experimental procedures
were carried out in accordance with the approved guidelines
and with the principles of the Declaration of Helsinki. All
participants were given written informed consent prior to
inclusion. Participants were contacted via advertisements in
local media to guarantee a community-based sample. An
experienced neuropsychologist (C.R.) clinically assessed all
individuals independently. Those who met dementia DSM-IV
diagnostic criteria on the basis of the neuropsychological and
clinical assessments were excluded. Moreover, exclusion criteria
included psychiatric or neurologic disorders, sustained head
injury, history of major medical disorders (neoplasm or cardiac
illness). Moreover, subjects were included if they had no alcohol
or drug abuse, no regular use of neuroleptics, antidepressants
or psychostimulants and no contraindications to MR imaging.
To control for the confounding effect of cardiovascular diseases,
individuals with subtle cardiovascular symptoms and a history of
stroke and transient ischemic episodes were also excluded from
the present study. The inclusion period for control subjects and
patients with MCI was from October 2010 to March 2016.
The final sample included 455 elderly individuals (mean
age, 73.5 ± 4.2 years, 263 females). Among them, 182
were subsequently classified in the sCON group (mean age,
73.1 ± 3 years, 112 females), 192 in the dCON group
(74.2 ± 4.1 years, 116 females), and 81 in the MCI group
(73.9± 5 years, 35 females).
Neuropsychological Assessment
At baseline (T1), all individuals underwent neuropsychological
assessment. The control and MCI participants were evaluated
with an extensive neuropsychological battery, including:
(a) Mini-Mental State Examination (MMSE) (Folstein et al.,
1975): the most often used short screening tool to provide
an overall measure of the cognitive impairment of the
subjects (Arevalo-Rodriguez et al., 2015);
(b) Hospitalized Anxiety and Depression scale (HAD)
(Zigmond and Snaith, 1983): self-assessment scale has
been developed and found to be a reliable instrument for
detecting states of depression and anxiety in the setting of
an hospital medical outpatient clinic;
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(c) Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) battery (Welsh et al., 1994): standardized battery
to assess various manifestations of Alzheimer’s disease.
(d) Clinical Dementia Rating scale (CDR) (Hughes et al., 1982):
clinical scale to investigate the staging of dementia.
(e) RI-48 Cued Recall Test (RI-48) (Buschke et al., 1997):
clinical test to investigate memory impairment.
Education level was defined according to the Swiss scholar
system: level 1, less than 9 years (primary school); level 2, between
9 and 12 years (high school); and level 3, more than 12 years
(university). Moreover, only cases with a CDR score of 0 and
scores within 1.5 standard deviations of the age-appropriate
mean in all other tests were included in the control group.
Participants with a CDR score of 0.5 but no dementia and
a score more than 1.5 standard deviations below the age-
appropriate mean in any of the previously mentioned tests were
confirmed to have MCI, in agreement with the criteria of Petersen
et al. (2001).
Eighteen months (±2 weeks) after the baseline evaluation
(T2), control subjects underwent cognitive reassessment with
the same neuropsychological battery. Participants were placed
in the dCON group at follow-up if they had a performance
0.5 standard deviation lower than that at inclusion for two
or more neuropsychological tests. Additionally, all individuals
were clinically assessed independently by two board certified
neuropsychologists (S.T., E.T.; 4 and 2 years of experience,
respectively). The final classification of dCON was made blindly
by a trained neuropsychologist (C.R., 10 years of experience)
using both the neuropsychological scores and clinical assessment.
For the extensive neuropsychological evaluation and clinical
tests scores at T1 see Supplementary Material and previously
published works (Xekardaki et al., 2015).
APOE Assessment
Whole blood samples were collected at baseline for all subjects
for APOE genotyping. Standard DNA extraction was performed
using either 9 ml EDTA tubes (Sarstedt, Germany) or Oragene
Saliva DNA Kit (DNA Genotek, Inc., Ottawa, ON, Canada)
which were stored at −20◦C. APOE genotyping was done on the
LightCycler (Roche Diagnostics, Basel, Switzerland) as described
previously (Nauck et al., 2000). Subjects were divided based on
if they were a carrier of the APOEε4 allele (ε4/ε3, ε3/ε3, ε3/ε2
carrier).
MRI Imaging
All participants underwent MRI examination including two
structural (T1 and T2) sequences.
Images were obtained using a 3T scanner (Trio; Siemens,
Erlangen, Germany) with a standard 32-channel head-coil.
A magnetization-prepared rapid gradient-echo three-
dimensional T1-weighted sequence was performed for spatial
normalization and gray matter segmentation with the following
fundamental parameters: 2300/2.3, 256 × 256 matrix, 176
sections, and 1 mm× 1 mm× 1 mm.
Additional sequences included axial fast spin-echo T2-
weighted imaging (4000/105, 30 sections, 4-mm section
thickness), susceptibility weighted imaging (28/20,
208 × 256 × 128 matrix, 1 mm × 1 mm × 1 mm voxel
size) were performed to exclude brain disease, such as ischemic
stroke, subdural hematomas, or space-occupying lesions.
Assessment of Gray Matter Volumes
FMRIB’s Integrated Registration and Segmentation Tool (FSL
FIRST1) was applied according to the standard procedure (de
Jong et al., 2008; Patenaude et al., 2011) to estimate left and right
gray matter volumes of the hippocampus and amygdala. FIRST is
part of FMRIB’s Software Library (FSL) and performs registration
and segmentation of these regions (Patenaude et al., 2011). The
3D T1 images are registered into MNI (Montreal Neurological
Institute) standard space, by means of affine transformations
based on 12 degrees of freedom. After registration, FSL-FIRST
applies ad hoc masks to locate the structures by segmentation
based on shape models and voxel intensities. ROIs were
defined using the Harvard-Oxford Subcortical Structural Atlas
implemented in FSL. The absolute volumes were calculated,
taking into account the transformations made in the first stage.
Subsequently, a boundary correction was used to determine
which boundary voxels belong to the structure or not. In this
study a Z-value of 3 was used, corresponding to a 99.998%
certainty that the voxel belonged to the subcortical structure. All
segmented regions were visually checked for errors in registration
and segmentation.
Brain tissue volume was estimated with SIENAX2 (Smith et al.,
2002), part of FSL (Smith et al., 2004). SIENAX extracts brain and
skull images from the single raw input data (Smith et al., 2002;
Woolrich et al., 2009). Tissue-type segmentation with partial
volume estimation was carried out to calculate total volume of
brain tissue (including volumes of gray matter, white matter).
For this study we used the absolute volumes generated by the
algorithm. Intracranial volume was calculated by adding the
volumes of cerebral spinal fluid, total gray matter and total white
matter.
After extracting the volumes of the identified areas (FIRST
and SIENAX-output) a one-way ANOVA group comparison was
performed including GM volumes as dependent variable, and
age, gender, educational level, APOE genotype and intracranial
volume as non-explanatory covariates. Tukey corrections for
multiple comparison was applied with a p< 0.05 threshold.
Moreover, after FIRST, vertex analysis was performed using
the standard procedure (Patenaude et al., 2011) and shape
changes were assessed on a per vertex basis. GM atrophy in the
vertices across all subjects was assessed using a general linear
model (GLM) with age as covariate using permutation-based
non-parametric testing (Randomize, part of FSL). Threshold-free
cluster enhancement (TFCE) multiple comparison correction
was applied, considering corrected p-values< 0.05 as significant.
Statistical Analysis
Group differences in age, gender, end education as well as
changes in neuropsychological scores between T1 and T2 were
1http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST
2http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA
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assessed using a one-way independent ANOVA with Tukey
correction for post hoc pair-wise comparisons. Correlations
between neuropsychological scores changes (delta T1–T2) and
GM volumes at baseline were assessed using Spearman rank
correlation coefficients. In addition, linear regression models
were built with the delta of cognitive scores as dependent
variable and MRI parameters at baseline, age, years of education,
and APOE genotyping as independent variables. Of note, the
variable gender was not considered in this linear regression
since a separate general regression analysis showed no differences
in cognitive performance between males and females within
each diagnostic group. Statistical analyses were performed using
GraphPad Prism (Version 6, GraphPad Software, San Diego,
CA, USA), R (Version 0.99.896, The R Project for Statistical
Computing) FSL (Version 5.0.6, FMRIB, Oxford, UK).
RESULTS
Demographic, Genetic, and
Neuropsychological Testing at T2
The dCON cases were slightly older than MCI cases (p < 0.05)
with no age differences between sCON and the other two
diagnostic groups [F(2,452) = 4.34, η2 = 0.2, p < 0.05]. A lower
proportion of women was found in MCI group (43%) compared
to sCON (61%) (p < 0.01) and dCON (60%) [F(2,452) = 4.34,
η2 = 0.02, p< 0.05]. Education level [F(2,452)= 2.42, η2 = 0.01,
p= 0.32] and APOE allele distribution did not differ between the
three groups [F(2,452)= 4.34, η2 = 0.02, p= 0.25].
Upon follow-up, higher MMSE scores were found in sCON
compared to dCON (p < 0.001) and MCI (p < 0.001)
and in dCON group compared to MCI cases (p < 0.01)
[F(2,452) = 26.54, η2 = 0.11, p < 0.001]. Moreover, significantly
lower HAD scores [F(2,452) = 5.16, η2 = 0.02, p < 0.01]
were found in sCON compared to MCI cases (p < 0.01). As
expected, dCON cases showed lower CDR scores compared to
MCI cases (p < 0.001) [F(2,452) = 1.6, η2 = 0.02, p < 0.001].
RI-48 performance was lower in MCI compared to dCON
(p < 0.001) and sCON (p < 0.001) and in dCON compared
to MCI (p < 0.001) [F(2,452) = 65, η2 = 0.3, p < 0.001].
Finally, significantly higher CERAD scores were found in sCON
compared to MCI (p< 0.05) [F(2,452)= 3.1, η2 = 0.05, p< 0.05]
(Table 1). For the results of the neuropsychological assessment at
T1, see Supplementary Material and Supplementary Table A.
Significant shape differences were found using vertex analyses
in the bilateral hippocampus and amygdala. In particular, GM
atrophy was more pronounced at the superior- posterior lateral
side of the structures both for the dCON compared to sCON
and for MCI compared to sCON (Figures 1E–H). No significant
contribution of age was observed.
Gray Matter Volumes
Significant differences were found in the volumes of the left
hippocampus [F(2,452) = 4.51, η2 = 0.015, p < 0.05], right
hippocampus [F(2,452) = 4.23, η2 = 0.014, p < 0.05] and right
amygdala [F(2,452) = 5.3, η2 = 0.02, p < 0.01] between sCON
and dCON (p < 0.05) as well as between sCON and MCI cases
(p < 0.05) (Figures 1A,B,D). Significant differences were found
in the volumes of the left amygdala between sCON and MCI cases
(p< 0.05) [F(2,452)= 3.54, η2 = 0.01, p< 0.05] (Figure 1C). No
significant differences were found between dCON and MCI in the
considered subcortical GM volumes.
In order to address the possible confounding effect of APOE
genotype and gender on the observed differences, we performed
a one-way ANOVA including GM volumes as dependent
variable, and age, gender, educational level, APOE genotype and
intracranial volume as non-explanatory covariates. Moreover, we
also repeated the analysis inserting in the model the interaction
APOExgender as non-explanatory variable. Our data persisted
after controlling for APOE and gender. In fact both variables were
not associated with GM volumes in the present sample.
Linear Regressions MRI Results –
Clinical Scores
Significant associations were found between gray matter
volume of left hippocampus and delta of MMSE and RI-
48 scores in dCON (MSSE: β-coefficient = 0.47, p < 0.001;
TABLE 1 | Demographic, genetic, and neuropsychological results at follow-up.
sCON dCON MCI p-value
(182) (192) (81) Group sCON vs. dCON sCON vs. MCI dCON vs. MCI
Age 73.1 ± 3.8 74.2 ± 4.1 73.1 ± 3 p < 0.05 η2 = 0.2 / / p < 0.05
Sex 61% f 60% f 43% f p < 0.01 η2 = 0.02 / p < 0.01 p < 0.01
Education 2.2 ± 0.7 2.1 ± 0.7 2.2 ± 0.6 / η2 = 0.01 / / /
APOE 17.5% ε4 20.3%% ε4 16% ε4 / η2 =0.02 / / /
MMSE 28.6 ± 1.1 27.9 ± 1.4 27.1 ± 2.2 p < 0.001 η2 = 0.11 p < 0.001 p < 0.001 p < 0.01
HAD 5.5 ± 3.4 6.1 ± 3.8 7.3 ± 4.3 p < 0.01 η2 = 0.02 / p < 0.01 /
CDR / 0.1 ± 0.1 0.4 ± 0.2 p < 0.001 η2 = 0.02 / / p < 0.001
RI-48 29.7 ± 5.4 26.3 ± 6.1 18.3 ± 6.9 p < 0.001 η2 = 0.3 p < 0.001 p < 0.001 p < 0.001
CERAD 10.8 ± 0.8 10.6 ± 0.9 10.4 ± 1.7 p < 0.05 η2 = 0.05 / p < 0.05 /
Mean and standard deviations are shown. η2 refers to eta-squared effect size of the ANOVA. sCON, stable controls; dCONs, deteriorating controls; MCI, mild cognitive
impairment; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; HAD, Hospitalized Anxiety and Depression scale; CDR, Clinical Dementia Rating scale; RI-48,
RI-48 Cued Recall Test; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease.
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FIGURE 1 | Significant atrophy was found in the volumes of the left hippocampus, right hippocampus, and right amygdala in stable controls (sCON)
compared to deteriorating controls (dCONs) (p < 0.05) and mild cognitive impairment (MCI) (p < 0.05) (A,B,D). Significant GM atrophy was found in the
volumes of the left amygdala between sCON and MCI (p < 0.05) (C). GM loss was more pronounced at the superior- posterior lateral side of both structures.
Significant atrophy for dCON compared to sCON was shown in blue, while atrophy for the MCI group compared to sCON was shown in green (E–H). No significant
differences were found between dCON and MCI in the considered subcortical GM volumes.
RI-48: β-coefficient = 0.51, p < 0.001) and MCI (MSSE:
β-coefficient = 0.65, p < 0.001; RI-48: β-coefficient = 0.18,
p< 0.01) groups (Figure 2).
DICUSSION
Our results show early atrophy of the bilateral hippocampus
and right amygdala that exist already in dCON, a group of
elderly controls displaying subtle cognitive deficits at 18 months
follow-up compatible with a pre-MCI stage (Jack et al., 2010).
A gradient effect is also present with MCI having the highest
GM volume loss in these limbic areas and dCON occupying an
intermediate position. Our results show that this population is
clinically and biologically distinguishable from healthy controls
(sCON), confirming previous studies suggesting that GM atrophy
in limbic areas predicts subsequent cognitive decline already in an
asymptomatic state preceding MCI (Jack et al., 2010; Edmonds
et al., 2015).
In mild AD, atrophy has a predilection for brain areas invaded
from NFTs. In agreement with this idea, early studies showed
that the volume of the medial temporal lobe discriminates
controls from both clinically overt AD and MCI cases. This
MRI parameter is also associated with time to progress from
MCI to AD (Atiya et al., 2003; Kantarci and Jack, 2003; Younes
et al., 2014). Previous investigations also indicated that baseline
measures of the hippocampus and amygdala in preclinical AD
patients predict subsequent development of MCI (Grundman
et al., 2002; den Heijer et al., 2006; Griffith et al., 2013; Guderian
et al., 2015). Our findings go beyond these data in that they
demonstrate that GM volume decrease is present bilaterally in
the hippocampus and in the right amygdala. This decrease is
more pronounced in the lateral side of the structures in elderly
controls that rapidly develop the first signs of cognitive decline
prior to MCI. In the same line, Perrotin et al. (2015) and Delli
Pizzi et al. (2016) reported that elderly individuals with subjective
cognitive decline as well as AD cases showed a major atrophy
of the lateral part of the CA1 field of the hippocampus and
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FIGURE 2 | Linear regression between atrophy in hippocampal volumes at T1 and differences in MMSE and RI-48 performance.
subiculum. Younes also reported that hippocampal and amygdala
GM atrophy occurs 2–4 years prior to the first signs of AD
(Younes et al., 2014). However, the GM loss in these areas varies
substantially in preclinical AD cases reflecting the heterogeneity
of the structural damage at this stage of the degenerative process
(Lauriola et al., 2016; Perrotin et al., 2016).
The association between this early structural damage and
amyloid pathology is still disputed. In its recent PET/MRI study,
Wang et al. (2015) suggested that amyloid pathology associated
with preclinical AD mostly affects hippocampal volume. In
contrast, Insel et al. (2015) showed that hippocampal atrophy
in preclinical AD cases may take place before Aβ positivity.
Interestingly, our observations also documented an association
between the extent of GM loss in left hippocampus and MMSE
and RI-48 scores decrement in dCON and MCI cases suggesting
that this MRI parameter may also serve as a marker of cognitive
changes in vulnerable cases at risk for AD (Apostolova et al., 2006;
Dinomais et al., 2016).
In our multivariate models, the association between lower
GM volume values in hippocampus and right amygdala at
baseline and dCON status persisted after correcting for possible
confounders and in particular APOE4 allele. Previous studies
indicated that, among cognitively normal individuals, APOE can
lead to hypo-metabolism in posterior cingulate cortex (Reiman
et al., 2004), worse cognitive performance (Caselli et al., 2009),
and smaller regional brain volumes (Shaw et al., 2007; Alexander
et al., 2012). Our results are consistent with the recent work by
Jack et al. (2015) showing no effect of APOE gene alleles on
memory and cognitive decline and with previous studies showing
no association between APOE ε4 and hippocampal volume in
cognitively normal individuals (Jack et al., 1998; Protas et al.,
2013; Lupton et al., 2016).
Strengths and Limitations
Strengths of the present study includes its longitudinal design,
large numbers of community-dwelling cases, as well as detailed
neuropsychological testing at inclusion and follow-up. However,
some limitations should also be considered. Consistent with
recent core clinical criteria for MCI (Albert et al., 2011), the
identification of dCONs was based on the objective decline
in cognitive functions measured using serial, comprehensive
neuropsychological assessments. However, in the absence of
longer follow-up the cognitive fate of these cases remains
uncertain so that they cannot be a priori considered as
incipient AD cases. No CSF measures of tau and Aβ protein
were available in this work so that the real extent of AD
pathology remains unknown. Future studies exploring the tau
and amyloid status based on PET in our community-based
cohort are warranted to examine the relationship between
AD molecular events and MRI atrophy in limbic areas in
dCON.
CONCLUSION
The present study focuses on detection of early cognitive
deterioration, showing that atrophy of the limbic system
(hippocampal and amygdala GM volume loss) is present and
predicts decline in cognitive performance in elderly healthy
individuals already before MCI.
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